Cencora, known for most of its modern history as AmerisourceBergen, is a company whose scale is entirely disproportionate to its public visibility. The modern corporate leviathan was formed in 2001 through the merger of AmeriSource Health and Bergen Brunswig, two major regional drug distributors. This merger was part of a relentless, multi-decade wave of consolidation within the pharmaceutical supply chain. Today, Cencora operates as part of an impenetrable "Big Three" oligopoly (alongside McKesson and Cardinal Health) that collectively controls roughly 90% of the entire pharmaceutical distribution market in the United States, effectively acting as the indispensable physical bridge between drug manufacturers and local pharmacies.
The Economics of the Middleman
The pharmaceutical wholesale business is a logistical marvel operating on razor-thin economics. An independent pharmacy cannot efficiently negotiate with, and receive daily shipments from, 500 different drug manufacturers (like Pfizer, Merck, and Eli Lilly). Instead, Cencora acts as the prominent central aggregator. It buys billions of dollars of drugs in bulk, stores them in automated, formidable regional distribution centers, and uses a considerable fleet of couriers to deliver exact, mixed orders of medications to tens of thousands of pharmacies overnight. Because they are essentially just moving boxes, the net profit margin is often less than 1%. The only way the business model survives is through astronomical, hundreds-of-billions-of-dollars scale.
The Walgreens Alliance
In 2013, recognizing the need to lock in, guaranteed volume to support its razor-thin margins, the company executed a strategic, decade-long partnership with Walgreens Boots Alliance. In exchange for granting Walgreens an equity stake in the company and significant board representation, Cencora secured the exclusive, multi-billion-dollar contract to supply the vast majority of Walgreens' major network of retail pharmacies globally. This strategic alliance insulated Cencora from the threat of Walgreens building its own internal distribution network and guaranteed the major, daily volume required to keep its distribution centers operating at maximum efficiency.
The Pivot to Specialty Drugs
While moving considerable pallets of generic ibuprofen to retail pharmacies provides the base volume, it generates very little profit. To drive actual earnings growth, Cencora pivoted toward "Specialty Distribution." Specialty drugs are the most complex, expensive medications on earth—often complex biologics used to treat cancer or rare genetic diseases. These drugs often cost tens of thousands of dollars per dose and require strict "cold chain" logistics (they must be maintained at exact temperatures or they are destroyed). Cencora dominates this specialized niche, providing complex logistics and patient support services directly to prominent hospital systems and oncology clinics, capturing significantly higher profit margins than the traditional retail business.
The Opioid Crisis and Rebranding
Because the Big Three distributors physically moved the vast majority of prescription opioids during the devastating American opioid epidemic, they faced formidable legal and political reckoning. Cencora, along with McKesson and Cardinal Health, faced thousands of lawsuits from states and municipalities, arguing the companies failed to monitor and report suspiciously large orders of addictive painkillers to small, rural pharmacies. In 2021, the three companies agreed to a historic, $21 billion global settlement to resolve the litigation. Following this damaging era, the company explicitly rebranded itself from AmerisourceBergen to Cencora in 2023, attempting to shed the historical baggage of the opioid crisis and unify its increasingly global, extensive portfolio of healthcare services under a single, modernized corporate identity.
